App-Quantinova.ai

Differential Expression of Interferon-Stimulated Genes in ANCA-Associated Vasculitis

Kotagiri Prasanti - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Interferon

An Inducible Model of Early Lupus Nephritis

Bhandari Aneesha - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

N/A

Glucocorticoid Toxicity in the Ponticelli Regimen

Huckle AbbyL - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Glucocorticoid

Investigating the Role of Complement in Membranous Nephropathy Using a Novel Ex Vivo Podocyte Model

Moran SarahMargaret - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Membranous glomerulonephritis

N/A

The NefIgArd trial: The Effect of Nefecon® (Budesonide) in Patients with Primary IgA Nephropathy at Risk of Developing ESRD

Barratt Jonathan - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

IgA nephropathy

Angiotensin II

Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers

Lo Jeannette - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

IgA nephropathy

BION-1301

Comparative Efficacy of Ravulizumab and Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome: An Indirect Comparison Using Clinical Trial Data

Rondeau Eric - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Atypical hemolytic uremic syndrome

Eculizumab

Steroid Treatment for the First Episode of Childhood Nephrotic Syndrome: Comparison of the 8- and 12-Week Regimen Using an Individual Patient Data Meta-Analysis

Schijvens AnneMerel - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Nephrotic syndrome

Prednisolone

Targeted B-Cell Depletion with Rituximab in Adult Relapsing Minimal Change Disease

Dattani Rakesh - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Minimal change disease

Rituximab

Long-Term Outcomes of Tacrolimus Treatment for Idiopathic Membranous Nephropathy

Nikolopoulou AikateriniK - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Membranous glomerulonephritis

Tacrolimus

Recurrent Membranous Post Transplantation: Histopathology, Treatment, and Outcomes

Gleeson Sarah - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

End stage renal disease

N/A

A New Approach to De Novo Minimal Change Disease in Pregnancy

Gleeson Sarah - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Minimal change disease

Enoxaparin

Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort

Petri Michelle - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

N/A

Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab vs. Azathioprine, After Rituximab Remission Induction for Patients with Relapsing ANCA-Associated Vasculitis

Smith RonaM - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Glucocorticoid

Validation of a Clinical-Pathologic Renal Risk Score in ANCA-Associated Glomerulonephritis: The US Experience

Kant Sam - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

ANCA-associated glomerulonephritis

N/A

Validation of the Renal Risk Score for ANCA-Associated Glomerulonephritis in a National Irish Cohort

Scott Jennifer - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

ANCA-associated glomerulonephritis

N/A

Anti-IL-5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): An 18-Month Follow-Up Study of a Steroid-Sparing Therapeutic Approach

Egan Allyson�Catherine - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Bag3 as a Potential Mechanoprotector in Podocytes

Plagmann Ingo - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Noncanonical PAR-1 Signalling Leads to Profibrotic Effects in Podocytes in Response to Steroid-Resistant Nephrotic Syndrome Disease Plasma

Chesor Musleeha - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Steroid-resistant nephrotic syndrome

RWJ-56110

TRPC6 Is a Key Mediator of a PAR-1 Activation Pathway in Podocytes That Is Responsible for FSGS

May CarlJ - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Nephrotic syndrome

N/A

Filters

45280 Abstracts